Use of Silodosin in preventing post-operative urinary retention after spine surgeries

Efficacy Of Oral Silodosin During Peri-Operative Period In Preventing Post-Operative Urinary Retention (POUR) In Spine Surgeries - A Randomised Controlled Trial - NIL

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096166

Enrollment

200

Registered

2025-10-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M968- Other intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified Health Condition 2: R339- Retention of urine, unspecified

Interventions

Intervention1: Oral Silodosin: Single dose of oral silodosin (8mg) is given 8 hours after surgery followed by another dose given 4 hours before the voiding trial (removal of foleys catheter), which wa

Eligibility

Inclusion criteria

Inclusion criteria: All patients above 18 years of age planned for spine surgery under general anaesthesia were included in the study.

Exclusion criteria

Exclusion criteria: Patients with neurological deficits, intra-operative dural tear, neurogenic bladder, cauda equina syndrome or conus medullaris syndrome who need indwelling catheter for a longer duration; Patients who are non-ambulatory and need indwelling catheter for longer duration of time. History of urinary retention requiring continuous or intermittent catheterization; Confirmed or suspected urethral stricture, history of prostatic or bladder neck surgery or cases of prostate cancer; History of unstable angina or myocardial infarction or cerebrovascular accidents with residual disease; History of syncope or orthostatic hypotension; An active prescription for an alpha receptor antagonist medication; Impaired renal function serum creatinine more than 1.4 mg/dL or eGFR less than 90 mg/mmol; Chronic Liver disease; Patients taking drugs that is known to have interaction with Silodosin - Clarithromycin, Anti-retroviral drugs, Ketoconazole/Itraconazole; Known allergy to Silodosin; Patients unwilling or unable to give consent

Design outcomes

Primary

Measure	Time frame
Primary outcome is the Incidence of Post operative urinary retention (POUR) in the post operative period after removal of Foleys catheter.Timepoint: 24 hours	—

Secondary

Measure	Time frame
Length of stay, Complications, ReadmissionTimepoint: 30 days	—

Countries

India

Contacts

Public ContactVidyadhara Srinivasa

Manipal Hospital, Old Airport Road, Bangalore

vidya007@gmail.com8948015165

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026